Who makes DUR-928 Topical Solution?

DUR-928 Topical Solution is developed by Durect.

What development phase is DUR-928 Topical Solution in?

DUR-928 Topical Solution is in Phase 2.

Last reviewed 2026-04-23 · How we verify

DUR-928 Topical Solution

Durect · Phase 2 active Small molecule

At a glance

Generic name	DUR-928 Topical Solution
Sponsor	Durect
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DUR-928 Topical Solution CI brief — competitive landscape report
DUR-928 Topical Solution updates RSS · CI watch RSS
Durect portfolio CI